Company: JUNS
Filing Date: 2025-11-06
Form Type: DEF 14A
Source: 0001493152-25-020988
Chunk: 1

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-06
Form: DEF 14A
Chunk 1
---
Your vote is very important.We encourage you to read the Proxy Statement and vote your shares as soon as possible. Whether or not you plan to attend, you can be sure your shares are represented at the Annual Meeting by promptly submitting your vote by the Internet, by telephone or, if you request a paper copy of the proxy materials and receive a proxy card, by mail.

On behalf of the Board of Directors, thank you for your continued confidence and investment in Jupiter.

| /s/                                      
 Christer Rosén                           |
| Christer                                 
 Rosén                                    |
| Chairman                                 
 of the Board and Chief Executive Officer |

<div align='center'>JUPITER NEUROSCIENCES, INC.

1001 North US HWY 1, Suite 504

Jupiter, FL 33477

Telephone: (561) 406-6154

NOTICE OF 2025 ANNUAL MEETING OF STOCKHOLDERS OF JUPITER NEUROSCIENCES, INC.

To Be Held on December 19, 2025 at 10:00 A.M. Eastern Time</div>

To the Stockholders of Jupiter Neurosciences, Inc.:

The 2025 Annual Meeting of Stockholders (the “ Annual Meeting”) of Jupiter Neurosciences, Inc., a Delaware corporation (“ Jupiter,” the “ Company,” “ us,” “ our,” or “ we”), will be held in a virtual meeting format on December 19, 2025 at 10:00 a.m. Eastern Time. You may attend, vote and submit questions during the Annual Meeting via the Internet at https://meetings.lumiconnect.com/200-142-773-960. We have designed the format of the Annual Meeting to ensure that you are afforded the same rights and opportunities to participate as you would at an in-person meeting, using online tools to ensure your access and participation.

The purpose of the Annual Meeting is to consider and act upon the following matters:

1. To elect seven (7) directors, the names of whom are set forth in the accompanying Proxy Statement, each to serve until the 2026 annual meeting of stockholders and until their respective successors are duly elected and qualified;

2. To approve an amendment to the Company’s certificate of incorporation to increase the authorized shares of common stock, par value $0.0001 per share (the “ Common Stock”), available for issuance from 125,000,000 shares to 500,000,000 shares;

3. To approve the adoption of the